Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Clinical trial NCT02453594 · COMPLETED
Trial details
- NCT number
- NCT02453594
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-10
- Primary completion
- 2023-09-18
- Enrollment
- 211
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.